Direct measurement of de novo lipogenesis has not previously been possible in humans. We measured de novo hepatic lipogenesis in normal men by means of stable isotopes and by combining the acetylated-xenobiotic probe technique with mass isotopomer analysis of secreted very low density lipoprotein-fatty acids (VLDL-FA). Sulfamethoxazole (SMX) was administered with [13C]acetate during an overnight fast followed by refeeding with intravenous glucose (7-10 mg/kg of weight per min), oral Ensure (7-10 mg of carbohydrate/kg of weight per min), or a high-carbohydrate mixed-meal breakfast (3.5 g of carbohydrate/kg of weight). Respiratory quotients remained less than 1.0. High-performance liquid chromatography/mass spectrometry-determined enrichments in SMX-acetate attained stable plateau values, and hepatic acetyl-coenzyme A (CoA) dilution rate did not increase with refeeding (approximately 0.024 mmol/kg per min). The fraction of VLDL-palmitate derived from de novo lipogenesis was only 0.91 +/-0.27% (fasted) and 1.64-1.97% (fed). For stearate, this was 0.37 +/-0.08% and 0.47-0.64%. Precursor enrichments predicted from isotopomer ratios were close to measured SMX-acetate enrichments, indicating that SMXacetate samples the true lipogenic acetyl-CoA pool. Stearate synthesis was less than palmitate and the two did not move in parallel. Estimated total VLDL-FA synthesis is less than 500 mg/day. Thus, de novo hepatic lipogenesis is a quantitatively minor pathway, consistent with gas exchange estimates; fatty acid futile cycling (oxidation/resynthesis) is not thermogenically significant; and synthesis […] Direct measurement oflipogenesis in humans has not been possible previously owing to a methodologic constraint. In order to measure the synthesis of FA (or any macromolecule) using tracers, one needs to know the labeling intensity (specific activity or enrichment) of the true biosynthetic precursor which, for lipogenesis, is cytosolic acetyl-CoA. In contrast to glycogen and protein synthesis, which occur in numerous tissues, the majority of lipogenesis probably occurs in liver in humans (9-1 1) and newly synthesized FA then enter the circulation in the form of very low density lipoprotein-triglyceride (VLDL-TG) and phospholipids. Accordingly, isotopic measurement of total lipogenesis in humans could in theory be achieved by sampling only blood if hepatic cytosolic acetylCoA were experimentally accessible.
Introduction
Direct measurement of de novo lipogenesis has not previously been possible in humans. We measured de novo hepatic lipogenesis in normal men by means of stable isotopes and by combining the acetylated-xenobiotic probe technique with mass isotopomer analysis of secreted very low density lipoproteinfatty acids (VLDL-FA). Sulfamethoxazole (SMX) was administered with ['3Clacetate during an overnight fast followed by refeeding with intravenous glucose (7-10 mg/kg of weight per min), oral Ensure (7-10 mg of carbohydrate/kg of weight per min), or a high-carbohydrate mixed-meal breakfast (3.5 g of carbohydrate/kg of weight). Respiratory quotients remained < 1.0. High-performance liquid chromatography/mass spectrometry-determined enrichments in SMX-acetate attained stable plateau values, and hepatic acetyl-coenzyme A (CoA) dilution rate did not increase with refeeding (-0.024 mmol/kg per min). The fraction of VLDL-palmitate derived from de novo lipogenesis was only 0.91±0.27% (fasted) and 1.64-1.97% (fed). For stearate, this was 037±0.08% and 0.47-0.64%. Precursor enrichments predicted from isotopomer ratios were close to measured SMX-acetate enrichments, indicating that SMX-acetate samples the true lipogenic acetyl-CoA pool. Stearate synthesis was less than palmitate and the two did not move in parallel. Estimated total VLDL-FA synthesis is < 500 mg/ day. Thus, de novo hepatic lipogenesis is a quantitatively minor pathway, consistent with gas exchange estimates; fatty acid futile cycling (oxidation/resynthesis) is not thermogenically significant; and synthesis rates of different nonessential fatty acids by human liver are not identical in nonoverfed normal men. The contribution and regulation of de novo lipogenesis in other settings can be studied using this technique. (J. Clin. Invest. 1991. 87:1841-1852.). Key words: carbohydrate disposal -high-performance liquid chromatography/mass spectrometry * isotopomers * nonessential fatty acids -precursor-product relationship * xenobiotic probes Portions of this work have appeared in abstract form (1989 Moreover, the lack of de novo lipogenesis would appear to be inconsistent with some clinical observations, for example, that high carbohydrate diets cause persistent hypertriglyceridemia in some human populations, including adult onset diabetics (5) (6) (7) and subjects with genetic dyslipidemias (8) . On the other hand, carbohydrate-induced hypertriglyceridemia could be due to increased FA reesterification or to altered triglyceride clearance rather than increased de novo lipogenesis. A definitive answer regarding the importance of the de novo pathway requires its direct measurement. Direct measurement oflipogenesis in humans has not been possible previously owing to a methodologic constraint. In order to measure the synthesis of FA (or any macromolecule) using tracers, one needs to know the labeling intensity (specific activity or enrichment) of the true biosynthetic precursor which, for lipogenesis, is cytosolic acetyl-CoA. In contrast to glycogen and protein synthesis, which occur in numerous tissues, the majority of lipogenesis probably occurs in liver in humans (9-1 1) and newly synthesized FA then enter the circulation in the form of very low density lipoprotein-triglyceride (VLDL-TG) and phospholipids. Accordingly, isotopic measurement of total lipogenesis in humans could in theory be achieved by sampling only blood if hepatic cytosolic acetylCoA were experimentally accessible.
We (12) (13) (14) (15) (16) (17) (18) (19) (20) and others (21-23) have previously sampled intrahepatic metabolites using the xenobiotic "probe" technique (Fig. 1) . One such probe is secreted acetaminophenglucuronide (GlcUA). This is derived from hepatic uridine di- phosphate (UDP)-GlcUA, which in turn derives exclusively from UDP-glucose. The labeling pattern in secreted GlcUA has been used for investigations of UDP-glucose biosynthesis in rats, humans, and dogs (12, 16, (20) (21) (22) . More recently, we (17) (18) (19) (20) have used acetylated xenobiotics as probes for hepatic cytosolic acetyl-CoA (Fig. 1) . We (20) have confirmed earlier reports (24) (25) (26) that acetylation of sulfa drugs such as sulfamethoxazole (SMX) occurs in parenchymal hepatocytes in the rat, not in extraparenchymal liver cells (27) (12, 19 etc. 
Modelfor calculation ofde novo lipogenesis
Traditionally, studies ofbiosynthesis have used radioactive isotopes or, when stable isotopes are used, the macromolecule has been hydrolyzed to its precursor units (i.e., enriched protein to ['3C]leucine). Comparison of precursor to product labeling has been straightforward because the existence ofisotopomers2 has not been an issue. This is so for radioisotopes because the average value for all molecular species is measured, i.e., specific activity is measured as the total disintegrations per minute per total mass present, and the existence of different subpopulations of labeled molecules is not relevant. In contrast, when one analyzes intact lipid molecules (C-16, C-18) using MS, each isotopomer will appear as a separate species. If, for example, one FA molecule ends up with two labeled acetates and another with zero, this is not identical analytically to two molecules having one labeled acetate in stable isotope studies whereas they would be identical with radioisotopes. The effect of isotopomer distribution on biosynthetic calculations therefore had to be addressed.
The relationship between an enriched precursor and the distribution of label in a macromolecular product is shown (Fig. 3) . The frequency of isotopomers in a product (e.g., VLDL-stearate, containing nine acetate units) synthesized from a precursor (e.g., enriched acetylCoA) can be predicted using the binomial expansion. This gives the likelihood of choosing x special (enriched) units out of n total units: (1) where n is the number of precursor units in product, x is the number of enriched precursor units in product, p is the probability ofeach precursor unit being enriched, and [ 
In intuitive terms, this is the problem of how often you will get one black ball and eight white balls if you draw nine balls from a box and the probability of each ball being black is p. What makes the application slightly more complex here is that there is a natural background p as well as the experimentally induced p. Moreover (Fig. 4 A) . SMX-acetate enrichments are used to represent hepatic acetyl-CoA enrichments (p).
With regard to the theoretical basis ofthe calculations, three further points should be made. First, precursor-product models are simpler mathematically if a steady-state enrichment is present in the precursor pool (38, 39) but the product enrichment need not attain a plateau during the experimental period for valid biosynthetic calculations (38-40). Secondly, the excess M + 2/excess M + 1 (EM + 2/EM + 1) isotopomer ratio is uniquely determined by the enrichment ofthe precursor (Fig. 4 B) . Conversely, the EM + 2/EM + 1 ratio uniquely predicts a true precursor enrichment. This relationship can be exploited experimentally as an internal check ofthe validity ofthe model, by comparing true precursor enrichments inferred from isotopomer frequencies to measured SMX-acetate enrichments. Finally, it is worth noting that lipid elongation will not be described by this model. However, this is unlikely to account for a significant amount oflabel in FAs because only one acetyl-CoA rather than a string ofacetyl-CoA units is added, in addition to its probably minor input quantitatively. (Fig. 5) . Thus, the dilution of hepatic acetyl-CoA relative to infused ['3C]acetate did not increase with carbohydrate feeding (Fig. 6 C) Fig. 7 A) . Interestingly, VLDL-stearate labeling did not always move in a parallel fashion (Table I, Fig. 7 B) (Table I ). The contribution of the de novo lipogenic pathway was calculated from the precursor-product relationship as described above (Table I, Fig. 8 ). After an overnight fast, de novo lipogenesis accounted for only 0.91±0.27% (mean±SE, n = I 1) of VLDLpalmitate and 0.37±0.08% (n = 11) of VLDL-stearate. Even after 8 h of refeeding with Ensure to deliver 7-10 mg/kg per min carbohydrate, the de novo pathway accounted for only 1.64±0.42% (n = 7) of VLDL-palmitate and 0.64±0.23% (n = 7) of VLDL-stearate (Fig. 8) . Results from Ensure refeeding, i.v. glucose refeeding and mixed meal refeeding were similar. In individual subjects, VLDL-stearate and VLDL-palmitate de novo synthesis did not necessarily move in parallel (Table I) . It is apparent that de novo lipogenesis contributes a very small fraction of circulating VLDL-palmitate and stearate under these dietary conditions. By inference, most circulating FA must either be derived from reesterification of preformed FFA or were "old" (not newly secreted during the 9-h isotope infusion period). Since the fractional catabolic rate of circulating VLDL-TG in humans is -0.30-0.50 h-' (i.e., half-life is important here. Plasma VLDL-TG concentrations were stable during the last 5 h of the refeeding period (not shown).
Other isotopomers (EM + 2/EM + I ratios). According to the model, the ratio of EM + 2/EM + 1 enrichments is uniquely determined by the enrichment of the true precursor (Fig. 4 B) thus can be used as a check on the accuracy of SMXacetate in reflecting the true precursor enrichment. The (M + 2) and (M + 1) isotopomers of VLDL-palmitate and stearate were analyzed in several subjects, and the binomial distribution was used to predict SMX-acetate enrichments based upon EM + 2/EM + 1 ratios (Table II) (Table II) supports the model in its broadest sense, i.e., not only for the appropriateness of the binomial distribution to represent this biosynthetic process but also for the accuracy of SMX-acetate (Fig. 1 addressed using indirect calorimetry in humans nor excluded as an important thermogenic factor. In cold-adapted rats, futile FA cycling is not a thermogenic mechanism (50) . Under physint (Fig. 4 B, Table II ). Inability to measure ologic conditions in normal humans, our results show that fuIoA specific activity in rats has limited the tile FA cycling does not make an important thermogenic conacetate as a tracer for lipogenesis measuretribution (est. < 500 mg/d [see below] -2 kcal/d). Indirect ice dilution occurs and mitochondrial acetylcalorimetry is based on a number of fairly complex assumppresented by plasma ketone bodies) is not in tions (45) , but for estimation of lipogenesis in normal subjects am with the cytosolic pool.? The xenobiotic our results indicate that the gas exchange approach is essentechnique resolves this problem and makes tially correct. As noted above, the absence ofde novo lipogeneicer for lipogenesis measurements in humans sis need not preclude a contribution from excess carbohydrate animals (17) . intake to hypertriglyceridemia (by inhibition of FA oxidation st application of the xenobiotic acetylation and diversion of hepatic FA into reesterification) but does npling acetyl-CoA in humans (Fig. 1) Some methodologic issues require comment. Assuming the half-life of circulating VLDL to be in the range of 1.5-2.0 h (41-44), essentially all circulating VLDL should represent newly secreted particles after a 7-9-h infusion (the duration of our tracer infusion during fasting and again during refeeding). A more complex question is whether all newly synthesized VLDL-FA in the liver will be secreted over this time period. The time lag between synthesis and secretion of VLDL from human hepatocytes is quite short, in the range of 20-30 min based on pulse-chase experiments (51) (52) (53) . VLDL is assembled in the lumen of the smooth endoplasmic reticulum (52) (53) (54) (55) , is secreted constitutively via trans-cisternal secretory vesicles, and does not accumulate in the liver except in disease states such as abetalipoproteinemia or alcoholic liver disease (52, 53, 56) . Moreover, during the course of our 16-h tracer experiments, > would represent -2% by weight ofa human liver, i.e., the flux is much greater than any preformed VLDL stores are likely to be. The possibility that dilution by preformed hepatic VLDL-FA is the reason for our low de novo lipogenesis estimates seems unlikely. Even if preformed VLDL in the liver diluted the secreted VLDL-FA by 50%, the contribution from de novo lipogenesis would still be < 5% (Table I) (63) . The dilution rate of hepatic acetyl-CoA relative to infused acetate tracer calculated from our results (Fig. 6 C) was 0.022-0.026 mmol/kg per min. The same parameter calculated by us recently in rats (17) was -0.158-0.200 mmol/kg per min, and by Block and Rittenberg (64) in rats using a comparable technique almost 40 years ago was 0. 132-0.153 mmol/ kg per min-consistent with the usual difference between rats and humans relating to metabolic body size (65) . This dilution parameter does not represent a true hepatic acetyl-CoA appearance rate, however, since infused acetate does not all enter the liver (in fact, most is taken up by peripheral tissues, references 66-68). We cannot therefore address the question why de novo lipogenesis proceeds at such a low rate in human liver: i.e., is the restriction at the level of PDH flux, acetyl-CoA carboxylase activity, FA synthase activity, or other steps in the pathway? This question may prove amenable to study using this isotopic technique, for example, by studying the effect of bypassing PDH via ethanol administration.
An interesting observation was that hepatic VLDL-stearate and palmitate synthesis are not identical or even parallel in humans (Table I, Fig. 8 Fig. 8 ), or only -200-500 mg/d. The energy cost of converting carbohydrate to fat before oxidation is estimated to be 28% of the energy content of the carbohydrate (70 
